Viatris Inc. VTRS SPXR3KPHARMA
Company Overview
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Why Investors Should Care
Offers a dividend yield of 2.95%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $14.30B (-3.0% YoY); net profit $-3.51B.
- Trailing 12 Months Year-on-year growth — revenue +4.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 3.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 3.46% |
| 1 Year: | 4.90% |
Stock Price Performance
| 1 Year: | +68.54% |
| 6 Months: | +22.02% |
| 3 Months: | +7.09% |
| 1 Month: | +4.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 2.95%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VTRS Viatris Inc. SPXR3KPHARMA | 16.88 | -45.62 | $19.39B | 2.95% | 0.84% | -2.75% | 3.46% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2.59B | 2.70B | 2.95B | 4.40B | 4.56B | 4.52B | 4.18B | 4.11B | 4.07B | 3.72B | 3.91B | 3.93B | 3.65B | 3.79B | 3.74B | 3.25B | 3.58B | 3.76B | 3.70B | 3.52B | 3.75B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.09B | 2.25B | 2.39B | 2.56B | 2.36B | - |
| Gross Profit | - | - | 906.10M | 1.03B | 1.16B | 1.13B | 1.33B | 1.57B | 1.77B | 1.70B | 1.75B | 1.54B | 1.61B | 1.69B | 1.50B | 1.45B | 1.46B | 1.16B | 1.33B | 1.37B | 1.15B | 1.16B | 1.46B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17B | 1.15B | 1.14B | 1.31B | 1.18B | - |
| Operating Income | - | - | 184.70M | 134.20M | 351.40M | -266.20M | -47.80M | 357.60M | 707.40M | 548.70M | 560.10M | 399.80M | 369.20M | 451.70M | 203.90M | -239.90M | 225.90M | -8.90M | 185.40M | 234.50M | -157.50M | -20.20M | 6.30M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.32B | 577.80M | 800.20M | 543.40M | 548.90M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.50M | 116.60M | 119.60M | 119.60M | 120.10M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.10B | -217.10M | -7.90M | -343.00M | -247.30M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -55.00M | -212.50M | 120.30M | -2.90M | -423.70M | - |
| Net Income | 0 | 0 | 0 | -900.00K | -169.00M | - | - | - | - | - | - | - | - | - | - | - | - | -3.04B | -4.60M | -128.20M | -340.10M | 176.40M | - |
| Diluted EPS | - | - | 0.04 | 0.08 | 0.36 | -0.86 | -0.23 | 0.26 | 0.33 | 0.26 | 0.29 | 0.19 | 0.22 | 0.27 | 0.09 | -0.27 | 0.08 | -2.55 | 0.00 | -0.11 | -0.30 | 0.15 | -0.10 |
| R&D Expense | - | - | 114.20M | 156.30M | 129.80M | 184.10M | 147.70M | 152.10M | 142.30M | 162.60M | 174.90M | 182.90M | 208.30M | 211.20M | 199.70M | 204.10M | 198.40M | 222.00M | 218.80M | 250.40M | - | 248.60M | 248.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 11.27B | 11.37B | 11.82B | 17.81B | 16.26B | 15.43B | 14.74B | 14.30B |
| Cost of Revenue | - | - | - | - | 9.77B | 8.99B | 9.12B | 9.29B |
| Gross Profit | 4.00B | 3.90B | 3.80B | 5.58B | 6.50B | 6.44B | 5.62B | 5.01B |
| Operating Expenses | - | - | - | - | 4.84B | 4.88B | 4.91B | 4.76B |
| Operating Income | 905.60M | 715.50M | -210.80M | -34.00M | 1.66B | 1.56B | 710.30M | 253.50M |
| EBITDA | - | - | - | - | 6.43B | 3.52B | 2.82B | -395.40M |
| Interest Expense | - | - | - | - | 592.40M | 573.10M | 550.00M | 471.30M |
| Pretax Income | - | - | - | - | 2.81B | 202.90M | -623.20M | -3.67B |
| Tax Provision | - | - | - | - | 734.60M | 148.20M | 11.00M | -150.10M |
| Net Income | - | 0 | - | - | 2.08B | 54.70M | -634.20M | -3.51B |
| Diluted EPS | 0.68 | 0.03 | -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 |
| R&D Expense | 704.50M | 639.90M | 555.10M | 751.10M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Feb 2019 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | 31.26B | 61.55B | - | 50.02B | 47.69B | 41.50B | 37.19B |
| Current Assets | - | - | - | - | - | - | 10.64B | 12.98B | 9.52B | 9.79B |
| Cash & Equivalents | - | 388.10M | - | 475.60M | 844.40M | - | 1.26B | 991.90M | 734.80M | 1.32B |
| Inventory | - | - | - | - | - | - | 3.52B | 3.47B | 3.85B | 4.00B |
| Receivables | - | - | - | - | - | - | 3.24B | 2.82B | 2.68B | 2.58B |
| Total Liabilities | - | - | - | 19.37B | 38.60B | - | 28.95B | 27.22B | 22.87B | 22.48B |
| Current Liabilities | - | - | - | 5.57B | 10.56B | - | 6.75B | 7.78B | 5.78B | 7.09B |
| Long Term Debt | - | - | - | 11.21B | 22.43B | - | 18.02B | 16.19B | 14.04B | 12.48B |
| Total Debt | - | - | - | - | - | - | 19.53B | 18.37B | 14.31B | 14.70B |
| Total Equity | 13.31B | 12.17B | 0 | 0 | 22.95B | - | 21.07B | 20.47B | 18.64B | 14.71B |
| Shares Outstanding | - | - | - | - | - | - | 1.21B | 1.22B | 1.23B | 1.25B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.34B | 1.80B | 1.23B | - | 3.00B | 2.90B | 2.30B | 2.32B |
| Investing Cash Flow | -1.21B | -525.40M | -301.10M | - | 1.47B | -864.50M | 1.80B | -427.70M |
| Financing Cash Flow | -1.09B | -1.17B | -605.70M | - | -3.88B | -2.30B | -4.33B | -1.29B |
| Capital Expenditure | -252.10M | -213.20M | -243.00M | - | -489.40M | -574.90M | -359.10M | -465.10M |
| Free Cash Flow | 2.09B | 1.59B | 988.80M | - | 2.51B | 2.33B | 1.94B | 1.85B |
| Net Change in Cash | - | - | - | - | 595.20M | -266.40M | -226.80M | 594.30M |
| Share Buybacks | 432.00M | 0 | 0 | 0 | 0 | 250.00M | 250.00M | 500.50M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 35.5% | 34.3% | 32.1% | 31.3% | 40.0% | 41.7% | 38.2% | 35.1% |
| Operating Margin % | 8.0% | 6.3% | -1.8% | -0.2% | 10.2% | 10.1% | 4.8% | 1.8% |
| Net Margin % | - | 0.0% | - | - | 12.8% | 0.4% | -4.3% | -24.6% |
| ROE % | - | - | - | - | 9.9% | 0.3% | -3.4% | -23.9% |
| ROCE % | - | 2.8% | -0.4% | - | 3.8% | 3.9% | 2.0% | 0.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 8.42% | 96.66M | $1.58B |
| 2 | Blackrock Inc. | 7.49% | 86.02M | $1.41B |
| 3 | Vanguard Capital Management LLC | 6.62% | 76.05M | $1.24B |
| 4 | Davis Selected Advisers | 6.55% | 75.23M | $1.23B |
| 5 | Price (T.Rowe) Associates Inc | 5.94% | 68.21M | $1.11B |
| 6 | Vanguard Portfolio Management LLC | 4.73% | 54.28M | $886.97M |
| 7 | State Street Corporation | 4.62% | 53.07M | $867.15M |
| 8 | Rubric Capital Management LP | 2.97% | 34.17M | $558.32M |
| 9 | Geode Capital Management, LLC | 2.86% | 32.81M | $536.08M |
| 10 | Dimensional Fund Advisors LP | 2.61% | 29.97M | $489.71M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VTRS
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s…
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept …
Viatris' China Policy Concerns Overstated, UBS Says
Viatris' (VTRS) China business remains resilient despite concerns over the country's new volume-cont
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million. Under the deal terms, Harrow will pay $30…
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Greater China surges 16% as management raises full-year guidance.
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
In early August 2026, Viatris Inc. reported higher second-quarter and year-to-date revenues, a six-month return to net profitability, raised its 2026 earnings guidance midpoint to US$14.75 billion, completed a US$1.15 billion share repurcha…
VTRS — Frequently Asked Questions
What is the current share price of Viatris Inc. (VTRS)?
As of 2026-09-07 16:24 PDT, Viatris Inc. (VTRS) trades at $16.88 on NasdaqGS. Its 52-week range is $9.17 to $17.73.
What is the market capitalisation of VTRS?
Viatris Inc. (VTRS) has a market capitalisation of $19.39B on NasdaqGS.
What is the P/E ratio of VTRS?
VTRS trades at a trailing price-to-earnings (P/E) ratio of -45.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.31.
Does VTRS pay a dividend?
Viatris Inc. (VTRS) currently offers a dividend yield of 2.95%.
What is the return on equity (ROE) of VTRS?
VTRS has a return on equity (ROE) of -2.75%. Its return on capital employed (ROCE) is 0.84%.
Is VTRS a good stock to buy?
This page provides a data-driven analysis of Viatris Inc. (VTRS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.